Psychedelics for addiction: promise, limits and caution

Psychedelic-assisted therapy has real and sometimes striking results for addiction and related conditions, but every expert here ties those results to a careful clinical setting, not to the drug alone. It is a guided, supervised and still experimental treatment, not a shortcut past the slow work of recovery.

Matthew Johnson of Johns Hopkins is the most optimistic and the most specific. He describes one to three high-dose psilocybin sessions producing change that lasts a year or more, including in smokers, and older Russian work using ketamine as a psychedelic therapy with high success rates for heroin and alcohol addiction. The model has four parts: psychiatric and heart screening, four to eight hours of preparation, a monitored dosing day with eyeshades and guides, and integration afterward. His leading explanation is a lasting change in how people see themselves, including labels such as smoker. He names the risks. Psychedelics can destabilize people prone to psychosis or mania. Even at Hopkins, about a third of people have a bad trip at some point in a session, and outside a protected setting panic has gotten people hurt or killed. Double-blind studies of microdosing found no benefit.

Anna Lembke, an addiction psychiatrist at Stanford, is optimistic about clinical use and alarmed about the culture. Addiction, she says, is a chronic, relapsing condition, and she doubts a quick fix. The supportive studies are small and short, in carefully selected people, always within psychotherapy. Of people taking psychedelics on their own for a spiritual awakening, she says, "That's a disaster and almost never works out well". She rejects the idea that psychedelics cannot be addictive and treats patients addicted to MDMA and to microdosing.

Andrew Huberman raises the obvious objection: an extreme chemical experience seems to violate what is known about dopamine and addiction. He also notes that people with addiction he knew got worse after MDMA therapy, while those with trauma did better. In his MDMA episode he reports the large trial for severe PTSD, in which 67 percent no longer met criteria afterward and many participants' substance problems also resolved. His guardrail is "MDMA taken on its own does not cure PTSD". He lays out the crash afterward, the unresolved question of neurotoxicity, and the danger of fentanyl in street drugs.

They agree that the setting is the treatment, that unsupervised use is the danger zone, that microdosing is unproven and that screening matters. They differ on how much to hope, on whether psychedelics can be addictive, and on who benefits most.

These compounds remained illegal federally at the time. If you are considering any of this, talk with a qualified physician or addiction specialist first, particularly if you have a psychiatric history, heart problems or take other medications.

What to do with it: treat psychedelics as a possible add-on to treatment, not a replacement. If interested, look for a clinical trial. Be honest in screening about personal and family psychiatric history. Do not self-medicate, and skip microdosing. Never trust street supply. Make no big decisions for two weeks after a session. Keep up the daily work of recovery afterward.